FDA approves Tremfya label expansion for joint damage inhibition in psoriatic arthritis, J&J says

Johnson & Johnson

Johnson & Johnson

JNJ

0.00
  • FDA cleared a label expansion for Johnson & Johnson’s TREMFYA to include inhibition of structural joint damage in adults with active psoriatic arthritis.
  • The update positions TREMFYA as the only IL-23 inhibitor with joint-damage inhibition evidence on its US label.
  • Decision was backed by 24-week Phase 3b APEX data, with radiographic progression cut 57% from Week 24 to Week 48 in switch patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605281910PR_NEWS_USPR_____NY70801) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.